Bionano Genomics, Inc. (BNGO) Fair Value 2026

BNGO · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 3 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Bionano Genomics, Inc. (BNGO) trades at $1.17, versus a $3.69 median fair value across its 3 active models — 215.0% above the current price. QOC: 5.8/10. Value Trap Risk: 42/100 (WARN). 3/13 models active.

Key Facts

Ticker
BNGO
Price
$1.17
Quality Score
5.8/10
Value Trap Risk
42/100
Models Active
3/13
Last Updated
Strength: Dynamic NAV suggests +408.7% upside with 52% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

Is Bionano Genomics, Inc. (BNGO) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Bionano Genomics, Inc. (BNGO) appears undervalued as of : the median of 3 independent fair value estimates is $3.69, 215.0% above the current price of $1.17. Estimates range from $0.52 to $5.95. BNGO scores 5.8/10 on fundamental quality and 42/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BNGO’s +215.0% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bionano Genomics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give BNGO?

3 Intrinsic Value Models vs. Current Price ($1.17)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.52 -55.3%
Asset-Based · High Conviction
 $5.95 +408.7%
Option-Based · Medium Conviction
 $3.69 +215.0%

All Models Active

All 3 models are displayed above.

What Is BNGO's Fair Value Range?

Spread across 3 independent models · $0.52 to $5.95

CirclFi's 3 active models place Bionano Genomics, Inc. (BNGO) between $0.52 and $5.95 per share, a spread of 147% of the median. The median of that range — $3.69 — is the fair value CirclFi publishes for BNGO, against a current price of $1.17.

Low · ML-RIVHigh · Dynamic NAV
$0.52median $3.69$5.95
Where the range comes from
Most bearish modelML Residual Income$0.52
Most bullish modelDynamic NAV$5.95
Model agreement2 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BNGO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BNGO, not a CirclFi price target. How each model works →

What Is Bionano Genomics, Inc. (BNGO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Bionano Genomics, Inc. at $1.17. With an estimated intrinsic value of $3.69 and 2 of 3 models pointing higher, the median implied return is +215.0%. The most optimistic model, Dynamic NAV, places fair value at $5.95 (+408.7%), while ML-RIV — the most conservative — estimates $0.52 (-55.3%). This +464.0% gap reflects genuine analytical uncertainty about Bionano Genomics, Inc.'s intrinsic worth.

What Do the Models Say About BNGO?

3 of 13 models are currently active for BNGO. Of these, 2 models suggest upside while 1 model suggests overvaluation. Taken together, their median fair value for BNGO is $3.69 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BNGO Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, BNGO ranks #41 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Bionano Genomics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BNGO a Value Trap?

CirclFi's Value Trap algorithm assigns BNGO a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Bionano Genomics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bionano Genomics, Inc. earns a quality score of 5.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +464.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BNGO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BNGO's 3 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bionano Genomics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

KMTSKestra Medical Technologies, Ltd.QOC 5.8HBIOHarvard Bioscience, Inc.QOC 5.8STXSStereotaxis, Inc.QOC 6.1CUPRCuprina Holdings (Cayman) LimitedQOC 5.6XRAYDENTSPLY SIRONA Inc.QOC 6.1NYXHNyxoah SAQOC 5.6ALCAlcon Inc.QOC 2.7RGENRepligen CorporationQOC 8.0OSUROraSure Technologies, Inc.QOC 6.8ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: KMTS · HBIO · STXS · CUPR · XRAY · NYXH · ALC · RGEN · OSUR · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to BNGO?

7 companies across all industries closest to BNGO’s Quality of Company score of 5.8/10.

NAMSNewAmsterdam Pharma Company N.V.QOC 5.8BCICBCP Investment Corp.QOC 5.8PRLDPrelude Therapeutics IncorporatedQOC 5.8UUUUniversal Safety Products, IncQOC 5.8ADMTADM Tronics Unlimited, Inc.QOC 5.8SPHLSpringview Holdings LtdQOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NAMS · BCIC · PRLD · UUU · ADMT · SPHL · NVDA

Where Does BNGO Sit in CirclFi's Medical Instruments & Supplies Rankings?

BNGO is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Bionano Genomics, Inc.’s Valuation?

What is Bionano Genomics, Inc.'s intrinsic value in 2026?

CirclFi puts Bionano Genomics, Inc. (BNGO)'s intrinsic value at $3.69 — the median of 3 independent model estimates as of 2026-08-28, ranging from $0.52 to $5.95. The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BNGO overvalued or undervalued right now?

At $1.17, 2 of 3 active models suggest BNGO may be undervalued, while 1 indicate potential overvaluation. The median of all 3 fair value estimates is $3.69, 215.0% above the current price of $1.17 — a consensus view that BNGO is undervalued. The assessment depends on which methodology best fits Bionano Genomics, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 5.8 mean for BNGO?

Bionano Genomics, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BNGO?

CirclFi analyzes BNGO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BNGO?

Of the 3 models currently active on BNGO, Dynamic NAV is the most bullish at $5.95 per share, and ML Residual Income is the most bearish at $0.52. CirclFi's published fair value for BNGO is the median of that range, $3.69, not either extreme. The gap between the two ends equals 147% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BNGO a value trap in 2026?

Bionano Genomics, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Bionano Genomics, Inc. (BNGO) has a median fair value of $3.69 — 215.0% above the current price of $1.17 — as of 2026-08-28.” Source: circlfi.com/stock/BNGO/ · Methodology
Primary sources for this BNGO valuation
  • Financial statements: Bionano Genomics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001411690) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BNGO as of ; valuations recomputed .